Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0TR9T
|
|||
Drug Name |
PMID27539678-Compound-17
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
GENZYME CORPORATION XIANG, Yibin HIRTH, Bradford KANE, John, L. LIAO, Junkai NOSON, Kevin YEE, Christopher
|
|||
Structure |
Download2D MOL |
|||
Formula |
C21H30N4O3
|
|||
Canonical SMILES |
CCCCCCCC1=NC(=NO1)C2=CC=C(C=C2)CNC(=O)C3C(CCN3)O
|
|||
InChI |
1S/C21H30N4O3/c1-2-3-4-5-6-7-18-24-20(25-28-18)16-10-8-15(9-11-16)14-23-21(27)19-17(26)12-13-22-19/h8-11,17,19,22,26H,2-7,12-14H2,1H3,(H,23,27)/t17-,19-/m0/s1
|
|||
InChIKey |
CMLALAZUOVTKKV-HKUYNNGSSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Sphingosine kinase 1 (SPHK1) | Target Info | Inhibitor | [1] |
Target's Patent Info | Sphingosine kinase 1 (SPHK1) | Target's Patent Info | [1] | |
BioCyc | Sphingosine and sphingosine-1-phosphate metabolism | |||
KEGG Pathway | Sphingolipid metabolism | |||
Metabolic pathways | ||||
Calcium signaling pathway | ||||
Sphingolipid signaling pathway | ||||
VEGF signaling pathway | ||||
Fc gamma R-mediated phagocytosis | ||||
Tuberculosis | ||||
NetPath Pathway | TCR Signaling Pathway | |||
TNFalpha Signaling Pathway | ||||
Panther Pathway | Angiogenesis | |||
VEGF signaling pathway | ||||
Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
Beta3 integrin cell surface interactions | ||||
S1P1 pathway | ||||
Sphingosine 1-phosphate (S1P) pathway | ||||
PDGFR-beta signaling pathway | ||||
Reactome | Sphingolipid de novo biosynthesis | |||
VEGFR2 mediated cell proliferation | ||||
WikiPathways | Signal Transduction of S1P Receptor | |||
Protein folding | ||||
Sphingolipid Metabolism |
References | Top | |||
---|---|---|---|---|
REF 1 | Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.